Related Experiment Video

Updated: May 10, 2026

The Lambda Select cII Mutation Detection System
07:08

The Lambda Select cII Mutation Detection System

Published on: April 26, 2018

Metformin's performance in in vitro and in vivo genetic toxicology studies

Juliane R Sant'Anna1, Joana Paula R S Yajima, Lúcia J Rosada

  • 1Laboratório de Genética de Microorganismos e Mutagênese, Departamento de Biotecnologia, Genética e Biologia Celular, Universidade Estadual de Maringá, 87020-900, Maringá, PR, Brazil.

Experimental Biology and Medicine (Maywood, N.J.)
|June 22, 2013
PubMed

Insights

Metformin, used for type 2 diabetes, was tested for cancer-causing effects. Studies show metformin is not mutagenic or recombinogenic at therapeutic concentrations, suggesting it does not induce secondary cancers.

Area of Science:

  • Pharmacology
  • Genetics
  • Oncology

Background:

  • Metformin is a primary treatment for type 2 diabetes mellitus.
  • Emerging research suggests metformin's potential anticancer properties in cell studies.
  • This study investigates metformin's safety regarding genotoxicity and carcinogenicity.

Purpose of the Study:

  • To evaluate the mutagenic and recombinogenic potentials of metformin.
  • To determine if metformin induces genetic damage at therapeutic plasma concentrations.
  • To assess metformin's risk as a secondary cancer inducer.

Main Methods:

  • Recombinogenic potential assessed using a homozygotization assay in Aspergillus nidulans.
  • Mutagenic potential evaluated via chromosome aberration and micronucleus tests in human lymphocytes.
  • Drug concentrations used were 12.5 µM, 25.0 µM, and 50.0 µM.

Main Results:

  • Metformin showed no statistically significant increase in homozygotization indices compared to controls.
  • No significant increase in numerical or structural chromosome aberrations was observed.
  • Metformin did not elevate micronuclei or nuclear buds in human lymphocytes.

Conclusions:

  • Metformin demonstrated a lack of recombinogenic activity in the Aspergillus nidulans assay.
  • Metformin exhibited no mutagenic activity in human lymphocyte tests.
  • Findings suggest metformin is not a secondary cancer inducer at pharmacological concentrations.
Keywords:
Aspergillus nidulansGenotoxicitychromosome aberrationshomozygotization assaymicronucleus assaymutagenicity

More Related Videos

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

Cellular Toxicity of Nanogenomedicine in MCF-7 Cell Line: MTT assay19:34

Cellular Toxicity of Nanogenomedicine in MCF-7 Cell Line: MTT assay

Published on: April 3, 2009

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
In-vitro Mutagenesis01:16

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
In vitro Mutagenesis01:16

In vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...